EA201990723A1 - Кристаллические формы - Google Patents

Кристаллические формы

Info

Publication number
EA201990723A1
EA201990723A1 EA201990723A EA201990723A EA201990723A1 EA 201990723 A1 EA201990723 A1 EA 201990723A1 EA 201990723 A EA201990723 A EA 201990723A EA 201990723 A EA201990723 A EA 201990723A EA 201990723 A1 EA201990723 A1 EA 201990723A1
Authority
EA
Eurasian Patent Office
Prior art keywords
crystalline forms
crystal forms
pharmaceutical compositions
phosphonopropionyl
methoxypyrrolidin
Prior art date
Application number
EA201990723A
Other languages
English (en)
Russian (ru)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of EA201990723A1 publication Critical patent/EA201990723A1/ru

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65583Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • A61K31/675Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
EA201990723A 2016-09-22 2017-09-21 Кристаллические формы EA201990723A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP2016072562 2016-09-22
PCT/EP2017/073858 WO2018055016A1 (en) 2016-09-22 2017-09-21 Crystalline forms

Publications (1)

Publication Number Publication Date
EA201990723A1 true EA201990723A1 (ru) 2019-10-31

Family

ID=59923448

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201990723A EA201990723A1 (ru) 2016-09-22 2017-09-21 Кристаллические формы

Country Status (27)

Country Link
US (4) US10730896B2 (enExample)
EP (2) EP3515924B1 (enExample)
JP (1) JP7097369B2 (enExample)
KR (1) KR102552795B1 (enExample)
CN (1) CN109715639B (enExample)
AU (1) AU2017331930B2 (enExample)
CA (1) CA3037794A1 (enExample)
CL (1) CL2019000728A1 (enExample)
CY (1) CY1125052T1 (enExample)
DK (1) DK3515924T3 (enExample)
EA (1) EA201990723A1 (enExample)
ES (1) ES2908572T3 (enExample)
HR (1) HRP20220234T1 (enExample)
HU (1) HUE057772T2 (enExample)
IL (1) IL265445B2 (enExample)
LT (1) LT3515924T (enExample)
MA (1) MA46266B1 (enExample)
MX (1) MX381590B (enExample)
MY (1) MY193080A (enExample)
PH (1) PH12019500567B1 (enExample)
PL (1) PL3515924T3 (enExample)
PT (1) PT3515924T (enExample)
RS (1) RS62946B1 (enExample)
SI (1) SI3515924T1 (enExample)
TW (1) TWI752086B (enExample)
UA (1) UA124073C2 (enExample)
WO (1) WO2018055016A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3515924T3 (da) 2016-09-22 2022-03-21 Idorsia Pharmaceuticals Ltd Krystallinske former
SG11201908128YA (en) 2017-03-15 2019-10-30 Idorsia Pharmaceuticals Ltd Subcutaneous administration of a p2y12 receptor antagonist
RS67649B1 (sr) 2020-07-15 2026-02-27 Viatris Asia Pacific Pte Ltd Vodena farmaceutska kompozicija koja sadrži antagonistu p2y12 receptora
IL309948A (en) * 2021-07-13 2024-03-01 Idorsia Pharmaceuticals Ltd A process for the synthesis of 4-((R)-2-{[6-((S)-3-methoxy-pyrrolidin-1-yl)-2-phenyl-pyrimidin-4-carbonyl]-amino}-3-phosphono- Propionyl)-piperazine-1-carboxylic acid butyl ester

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5373586A (en) 1976-12-09 1978-06-30 Mitsubishi Chem Ind Ltd New penicillin derivatives
CA2020437A1 (en) 1989-07-05 1991-01-06 Yoshihide Fuse Cinnamamide derivative
ES2248084T3 (es) 1999-06-14 2006-03-16 Eli Lilly And Company Inhibidores de serinproteasa.
US6861424B2 (en) 2001-06-06 2005-03-01 Schering Aktiengesellschaft Platelet adenosine diphosphate receptor antagonists
EA200500899A1 (ru) 2002-12-11 2006-02-24 Шеринг Акциенгезельшафт Антагонисты аденозиндифосфатного рецептора тромбоцитов
US7253153B2 (en) 2003-04-09 2007-08-07 Wyeth Derivatives of [2-(8,9-dioxo-2,6-diazabicyclo[5.2.0]non-1(7)-en-2-yl)alkyl] phosphonic acid and methods of use thereof
TW200640877A (en) 2005-04-28 2006-12-01 Actelion Pharmaceuticals Ltd Pyrimidine derivatives
TWI382976B (zh) 2005-10-21 2013-01-21 Actelion Pharmaceuticals Ltd 作為抗瘧疾劑之新穎哌
CL2007002920A1 (es) 2006-10-13 2008-06-06 Actelion Pharmaceuticals Ltd Compuestos derivados de 2-aminocarbonilpiridina; composicion farmaceutica; y uso para el tratamiento de trastornos vasculares oclusivos.
AR063518A1 (es) 2006-10-25 2009-01-28 Actelion Pharmaceuticals Ltd Derivados 2-fenil-6-aminocarbonil-pirimidina; composicion farmaceutica; y su uso para tratar y/o prevenir enfermedades vasculares perifericas viscerales, hepaticas y renales, enfermedades cardiovasculares y enfermedades cerebrovasculares asociados con la agregacion de plaquetas, incluyendo trombosis
JP4785881B2 (ja) 2007-02-27 2011-10-05 大塚製薬株式会社 医薬
WO2008128647A1 (en) 2007-04-23 2008-10-30 Sanofi-Aventis Quinoline-carboxamide derivatives as p2y12 antagonists
JP4729133B2 (ja) 2007-11-29 2011-07-20 アクテリオン ファーマシューティカルズ リミテッド ホスホン酸誘導体及びp2y12受容体拮抗剤としてのそれらの使用
EP2238127B1 (en) 2007-12-26 2012-08-15 Sanofi Pyrazole-carboxamide derivatives as p2y12 antagonists
WO2009080226A2 (en) 2007-12-26 2009-07-02 Sanofis-Aventis Heterocyclic pyrazole-carboxamides as p2y12 antagonists
AR071652A1 (es) 2008-04-11 2010-07-07 Actelion Pharmaceuticals Ltd Derivados 2- fenil-piridina substituidos
AR071653A1 (es) 2008-04-11 2010-07-07 Actelion Pharmaceuticals Ltd Derivados 2-fenil-4-ciclopropil-pirimidina
CA2756542C (en) 2009-04-08 2017-08-22 Actelion Pharmaceuticals Ltd 6-(3-aza-bicyclo[3.1.0]hex-3-yl)-2-phenyl-pyrimidines
CA2756654C (en) 2009-04-22 2017-08-22 Actelion Pharmaceuticals Ltd Thiazole derivatives and their use as p2y12 receptor antagonists
DK3515924T3 (da) 2016-09-22 2022-03-21 Idorsia Pharmaceuticals Ltd Krystallinske former
SG11201908128YA (en) 2017-03-15 2019-10-30 Idorsia Pharmaceuticals Ltd Subcutaneous administration of a p2y12 receptor antagonist
RS67649B1 (sr) 2020-07-15 2026-02-27 Viatris Asia Pacific Pte Ltd Vodena farmaceutska kompozicija koja sadrži antagonistu p2y12 receptora

Also Published As

Publication number Publication date
PH12019500567A1 (en) 2019-11-18
US11365209B2 (en) 2022-06-21
IL265445A (en) 2019-05-30
MA46266A (fr) 2019-07-31
JP7097369B2 (ja) 2022-07-07
BR112019004845A2 (pt) 2019-06-04
MY193080A (en) 2022-09-26
CL2019000728A1 (es) 2019-07-05
EP3515924B1 (en) 2021-12-15
JP2019529553A (ja) 2019-10-17
US20200017534A1 (en) 2020-01-16
KR102552795B1 (ko) 2023-07-06
PH12019500567B1 (en) 2024-01-31
US12227532B2 (en) 2025-02-18
TW201813965A (zh) 2018-04-16
US20210009614A1 (en) 2021-01-14
AU2017331930A1 (en) 2019-03-07
HRP20220234T1 (hr) 2022-05-13
MA46266B1 (fr) 2022-02-28
IL265445B1 (en) 2024-01-01
LT3515924T (lt) 2022-03-10
ES2908572T3 (es) 2022-05-03
KR20190052704A (ko) 2019-05-16
MX2019003093A (es) 2019-07-18
EP3981774A1 (en) 2022-04-13
DK3515924T3 (da) 2022-03-21
IL265445B2 (en) 2024-05-01
CA3037794A1 (en) 2018-03-29
US20220275011A1 (en) 2022-09-01
AU2017331930B2 (en) 2021-07-15
CN109715639B (zh) 2022-04-19
TWI752086B (zh) 2022-01-11
US20250163086A1 (en) 2025-05-22
EP3515924A1 (en) 2019-07-31
CN109715639A (zh) 2019-05-03
CY1125052T1 (el) 2024-02-16
US10730896B2 (en) 2020-08-04
PL3515924T3 (pl) 2022-04-11
RS62946B1 (sr) 2022-03-31
WO2018055016A1 (en) 2018-03-29
MX381590B (es) 2025-03-12
SI3515924T1 (sl) 2022-04-29
PT3515924T (pt) 2022-03-11
UA124073C2 (uk) 2021-07-14
HUE057772T2 (hu) 2022-06-28
NZ750772A (en) 2023-10-27

Similar Documents

Publication Publication Date Title
EA201990388A1 (ru) Пиперидиновые модуляторы рецепторов cxcr7
CY1121843T1 (el) Σκευασματα ετανερσεπτης σταθεροποιημενα με ιοντα μαγνησιου
EA201790389A1 (ru) Пирролопиримидиновые соединения, используемые в качестве агониста tlr7
BR112016015365A8 (pt) composto, composição farmacêutica e uso de um composto
SA517390583B1 (ar) مشتقات حمض أميني جديدة، عملية لتحضيرها وتركيبات صيدلية تحتوي عليها
BR112017013491A2 (pt) compostos de pirimidina fundida para o tratamento de hiv
MD4650B1 (ro) Derivaţi de chinazolină utilizaţi în tratamentul HIV
MX379155B (es) Compuestos que inhiben la proteína mcl-1.
MX381487B (es) Ciertos inhibidores de la proteina quinasa.
MD20160012A2 (ro) Formulare de inhibitori SYK
CY1121596T1 (el) Αμιδια βενζοξαζινονης ως αλατοκορτικοειδεις ρυθμιστες υποδοχεα
BR112017019653A2 (pt) derivados heteroaril bicíclicos fundidos tendo atividade como inibidores de phd
CY1125052T1 (el) Κρυσταλλικες μορφες
EA201690888A1 (ru) Новые гетероциклические соединения
EA201791896A1 (ru) Дезацетокситубулизин н и его аналоги
EA029499B9 (ru) Ингибиторы rorc2 и способы их применения
EA201690390A1 (ru) Производные амидов в качестве антагонистов рецептора к лизофосфатидной кислоте
PH12017501280A1 (en) Hydroxyalkyl-piperazine derivatives as cxcr3 receptor modulators
CY1123877T1 (el) Μορφες στερεας καταστασης αλατων νιλοτινιμπης
EA201501163A1 (ru) Модуляторы рецептора cxcr7
MX2017009292A (es) Derivados de (r)-2-metil-piperazina como moduladores del receptor cxcr3.
JOP20170115B1 (ar) مشتقات بيريدينيل، تركيبات صيدلية منها واستخداماتها كمثبطات aoc3
BR112016002724A8 (pt) composto, processo para a preparação de um composto, composição farmacêutica e uso de composto
EA201791397A1 (ru) СВЯЗАННЫЕ С ГЕТЕРОЦИКЛИЛАМИ ПРОИЗВОДНЫЕ ИМИДАЗОПИРИДАЗИНА В КАЧЕСТВЕ ИНГИБИТОРОВ PI3Kβ
EA201890726A1 (ru) Кристаллические формы